J1323 Elranatamab Injection Reimbursement | OpenPayer

Summary & Overview

HCPCS Level II J1323: Elranatamab-bcmm Injection, 1 mg

HCPCS Level II code J1323 denotes a 1 mg unit of elranatamab-bcmm, an injectable oncology biologic used in parenteral therapy. The code is used for billing physician‑administered doses in outpatient infusion centers and oncology clinics and matters nationally as novel biologic agents increasingly factor into specialty drug spend and site-of-care decisions. Payers commonly addressing coverage include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

This publication provides national context for billing and coding of J1323, focusing on benchmark pricing, payer coverage patterns, and clinical service context for administration. Readers will find concise explanations of what the code represents, typical sites of service, and the common modifiers associated with injectable physician‑administered drugs (listed elsewhere). The report also outlines expected reporting practices for unit-based HCPCS Level II codes and highlights considerations that affect claim submission and reimbursement for specialty biologics. Data not available in the input where specific benchmark or taxonomy details would normally appear.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ1323HCPCS Level IIelranatamaboncologyinjectable biologicinfusion clinicphysician-administeredspecialty drug

Billing Code Overview

HCPCS Level II code J1323 represents injection, elranatamab-bcmm, 1 mg, an injectable oncology biologic. The service type is administration of a physician-administered injectable medication. The typical site of service is outpatient infusion or oncology clinic settings where parenteral biologic therapies are delivered.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with relapsed or refractory multiple myeloma presents for administration of J1323 (elranatamab-bcmm, 1 mg). The patient is evaluated in the outpatient oncology infusion clinic for baseline vital signs, review of recent labs including complete blood count, comprehensive metabolic panel, and disease markers (serum free light chains, M-protein). The oncology nurse verifies premedication orders (acetaminophen, antihistamine, corticosteroid per institutional protocol) and confirms the presence of an indwelling peripheral IV or implanted port. The first dose is given under close observation for cytokine release syndrome and infusion-related reactions; vital signs are monitored frequently during and for several hours after the injection. Subsequent injections are scheduled per the drug’s dosing regimen, typically in the outpatient infusion center or hospital outpatient department; dose adjustments or supportive measures are documented in the chart. The clinical workflow includes medication verification by pharmacy, documentation of lot number and units administered, billing of J1323 per milligram administered, and use of applicable modifier codes to indicate circumstances such as physician supervision, partial administration, or discarded drug. Typical sites of service are outpatient infusion centers, hospital outpatient departments, or, occasionally, inpatient oncology units for patients requiring close monitoring. Common clinical considerations include hematologic monitoring, infection surveillance, and management plans for infusion reactions and immune-mediated adverse events.

Coding Specifications

Modifier	Description	When to Use

HCPCS Level II J8501: Aprepitant, Oral, 5 mg

HCPCS-J0596-RUCONEST-C1-ESTERASE-INHIBITOR-RECOMBINANT-INJECTION

HCPCS J0596: c1 Esterase Inhibitor (Recombinant) Injection, Ruconest

HCPCS-J2021-LINEZOLID-INJECTION-200MG-HOSPIRA

HCPCS J2021: Linezolid Injection, 200 mg

HCPCS-J7192-FACTOR-VIII-RECOMBINANT-PER-IU

HCPCS J7192: Factor VIII (recombinant) per International Unit

HCPCS-J3101-TENECTEPLASE-INJECTION-1MG

HCPCS J3101: Injection, Tenecteplase, 1 mg

HCPCS-J7325-HYALURONAN-SYNVISC-INTRA-ARTICULAR-INJECTION

HCPCS J7325: Hyaluronan (Synvisc) for Intra-articular Injection, 1 mg

HCPCS-J0690-CEFAZOLIN-500MG-INJECTION

HCPCS Level II J0690: Injection, Cefazolin Sodium, 500 mg

HCPCS-J8999-ORAL-CHEMOTHERAPEUTIC-DRUG-PRESCRIPTION-NOS

HCPCS Level II J8999: Prescription Oral Chemotherapeutic Drug, NOS

HCPCS-J7207-FACTOR-VIII-RECOMBINANT-PEGYLATED-INJECTION

HCPCS J7207: Factor VIII (Recombinant, Pegylated) Injection

HCPCS-J7356-FOSCARBIDOPA-FOSLEVODOPA-INJECTION

HCPCS J7356: Injection, foscarbidopa 0.25 mg/foslevodopa 5 mg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`208000000X`	Hematology & Medical Oncology	Most common specialty ordering and managing `J1323` administration
`207K00000X`	Allergy & Immunology	Involved when immune-mediated adverse events or specialized management is required
`163W00000X`	Hematology	Specialists who manage complex myeloma patients and coordinate therapy
`363L00000X`	Infusion Nursing	Nurses specializing in outpatient infusion administration and monitoring
`207Q00000X`	Medical Oncology	Oncology clinicians supervising outpatient administration and follow-up

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C90.00`	Multiple myeloma not having achieved remission	Primary indication for elranatamab in relapsed/refractory settings
`C90.01`	Multiple myeloma in remission	Relevant for history and ongoing surveillance in patients receiving maintenance or subsequent therapy
`D47.Z2`	Monoclonal gammopathy of undetermined significance (MGUS)	Pre-malignant plasma cell disorder in differential diagnosis and progression surveillance
`C90.02`	Multiple myeloma in relapse	Directly relevant when dosing `J1323` for relapsed disease
`T88.7XXA`	Unspecified adverse effect of drug or medicament, initial encounter	Used for documentation when managing infusion-related or immune-mediated adverse effects during administration

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Commonly billed for the time-based IV infusion portion when `J1323` is administered intravenously or via protocols that require infusion time tracking
`96415`	Chemotherapy administration, IV infusion; each additional hour	Billed when infusion of `J1323` extends beyond the unit time covered by the initial infusion code
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used when `J1323` is administered by subcutaneous injection rather than IV, if clinically appropriate
`36415`	Collection of venous blood by venipuncture	Performed for pre- and post-administration laboratory monitoring associated with `J1323`
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used for established patient visits involving evaluation and management related to therapy planning, adverse event assessment, or follow-up

`00`	No modifier	Rarely used; default when no specific modifier applies
`22`	Increased procedural services	Use when documentation supports substantially greater service complexity related to administration or management
`23`	Unusual anesthesia	Use if unusual anesthesia is required for administration (rare for `J1323`)
`52`	Reduced services	Use when a planned portion of the service was not provided
`53`	Discontinued procedure	Use when the administration is started but discontinued due to patient condition
`55`	Postoperative management only	Use if only post-administration management is billed separately (in limited scenarios)
`56`	Preoperative management only	Use if only pre-administration management is billed separately (uncommon)
`62`	Two surgeons	Use if two physicians of different specialties actively participate in the administration or management
`78`	Unplanned return to operating/procedure room by same physician following initial procedure	Use if patient requires immediate repeat procedure related to the administration
`80`	Assistant surgeon	Use when an assistant surgeon actively assists (rare for infusion services)
`JW`	Drug discarded/not administered	Use to indicate that a portion of a single-use vial was discarded and not administered to the patient
`JZ`	No drugs discarded (no wastage)	Use to indicate no portion of the dispensed drug was discarded
`KX`	Requirements specified in the medical policy are met	Use when documentation supports medical necessity per payer-specific coverage criteria
`QX`	CRNA service with physician direction	Use when a certified registered nurse anesthetist provides anesthesia under physician direction (rare)

OpenPayer